Education
About Us
Working with TipRanks
Follow Us
Ypsomed Holding AG (CH:YPSN)
:YPSN
Top Page
Ypsomed Holding AG
(LSE:YPSN)
60Neutral
Ypsomed Holding AG (YPSN) vs. S&P 500 (SPY)
Market Cap
CHF4.58B
Dividend Yield0.6%
Average Volume (3M)16.40K
Price to Earnings (P/E)61.6
Beta (1Y)0.64
Revenue Growth21.33%
EPS Growth2.72%
CountryCH
Employees2,600
SectorHealthcare
Sector Strength69
IndustryMedical - Equipment & Services
Share Statistics
EPS (TTM)5.45
Shares Outstanding13,649,739
10 Day Avg. Volume14,281
30 Day Avg. Volume16,402
Financial Highlights & Ratios
PEG Ratio22.67
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF430.33Price Target Upside28.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Ypsomed Holding AG Business Overview & Revenue Model
Company DescriptionYpsomed Holding AG (YPSN) is a Swiss-based company engaged in the development and manufacturing of injection and infusion systems for self-medication, with a focus on diabetes management. It operates in the medical technology sector, providing innovative solutions for insulin delivery and other therapeutic areas. The company offers a range of products, including insulin pumps, pen injectors, and related accessories, catering to both healthcare professionals and patients.
How the Company Makes MoneyYpsomed Holding AG generates revenue primarily through the sale of its medical devices and solutions for self-medication. Key revenue streams include the direct sale of insulin pumps, pen injectors, and infusion sets, as well as the provision of related services. The company also licenses its technology to pharmaceutical companies, which contributes to its earnings. Significant partnerships with global pharmaceutical companies enhance its market reach and product distribution, further driving revenue growth. Ypsomed's focus on innovation and expanding its product portfolio supports its financial performance in the competitive medical technology industry.
Ypsomed Holding AG Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 548.46M | 497.46M | 464.84M | 403.66M | 394.26M | Gross Profit |
| 189.05M | 140.59M | 113.82M | 94.83M | 90.97M | EBIT |
| 86.22M | 37.30M | 24.40M | 769.00K | 1.82M | EBITDA |
| 161.78M | 137.51M | 92.48M | 63.86M | 61.63M | Net Income Common Stockholders |
| 78.37M | 51.27M | 23.11M | 5.81M | 11.73M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 74.02M | 25.22M | 17.04M | 22.41M | 22.33M | Total Assets |
| 1.10B | 861.88M | 756.91M | 717.68M | 678.24M | Total Debt |
| 256.00M | 157.00M | 267.00M | 215.00M | 193.00M | Net Debt |
| 181.98M | 132.52M | 251.14M | 196.85M | 180.83M | Total Liabilities |
| 483.66M | 291.57M | 356.63M | 313.54M | 292.89M | Stockholders Equity |
| 617.74M | 562.33M | 392.54M | 395.38M | 377.66M |
| Cash Flow | Free Cash Flow | |||
| -32.09M | -39.64M | -41.72M | -40.75M | -69.64M | Operating Cash Flow |
| 163.22M | 129.53M | 85.71M | 85.83M | 49.09M | Investing Cash Flow |
| -195.07M | -122.02M | -125.70M | -106.91M | -115.83M | Financing Cash Flow |
| 81.07M | 1.26M | 38.12M | 26.67M | 68.66M |
Ypsomed Holding AG Technical Analysis
Neutral
336.00
Price Trends
342.73
Negative
347.61
Negative
375.39
Negative
Market Momentum
-5.25
Negative
49.16
Neutral
41.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:YPSN, the sentiment is Neutral. The current price of 336 is above the 20-day moving average (MA) of 329.25, below the 50-day MA of 342.73, and below the 200-day MA of 375.39, indicating a neutral trend. The MACD of -5.25 indicates Negative momentum. The RSI at 49.16 is Neutral, neither overbought nor oversold. The STOCH value of 41.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:YPSN.
Ypsomed Holding AG Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | CHF4.00B | 24.45 | 18.36% | 0.37% | 1.82% | 39.11% | |
61 Neutral | CHF2.63B | 37.17 | 20.81% | 0.40% | 13.35% | 50.65% | |
60 Neutral | CHF4.58B | 61.61 | 12.44% | 0.60% | 21.33% | 2.72% | |
58 Neutral | $1.90B | 28.00 | 4.84% | 1.89% | -13.04% | -48.74% | |
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% |
* Healthcare Sector Average
Performance Comparison
CH:YPSN
Ypsomed Holding AG
341.50
5.67
1.69%
CH:MOVE
Medacta Group SA
129.60
19.52
17.74%
CH:SFZN
Siegfried Holding AG
930.00
61.29
7.06%
CH:TECN
Tecan Group AG
151.30
-174.37
-53.54%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.